(Q34040906)

30 July 2017

title

Mericitabine and ritonavir-boosted danoprevir with or without ribavirin in treatment-naive HCV genotype 1 patients: INFORM-SVR study (English)

1 reference

30 July 2017

1 reference

1 reference

1 reference

3

Stefan Zeuzem

1 reference

30 July 2017

4

Patrick Marcellin

1 reference

30 July 2017

Edward J Gane

1

1 reference

30 July 2017

Paul J Pockros

2

1 reference

30 July 2017

Anna Shikhman

5

1 reference

30 July 2017

Coen Bernaards

6

1 reference

30 July 2017

Julian Zhou

7

1 reference

30 July 2017

Ellen S Yetzer

8

1 reference

30 July 2017

Rosa Ballester

9

1 reference

30 July 2017

Cindy Dwyer

10

1 reference

30 July 2017

Xiao Tong

11

1 reference

30 July 2017

Isabel Nájera

12

1 reference

30 July 2017

Anne Bertasso

13

1 reference

30 July 2017

Janet Hammond

14

1 reference

30 July 2017

Amy Kindrick

15

1 reference

30 July 2017

Peter N Morcos

16

1 reference

30 July 2017

Patrick Smith

17

1 reference

30 July 2017

Saray Stancic

18

1 reference

30 July 2017

Nancy S Shulman

19

1 reference

30 July 2017

publication date

19 June 2014

1 reference

30 July 2017

1 reference

30 July 2017

volume

35

1 reference

30 July 2017

issue

1

1 reference

30 July 2017

page(s)

79-89

1 reference

An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases

30 July 2017

cites work

1 reference

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

21 January 2018

1 reference

Sofosbuvir for previously untreated chronic hepatitis C infection

21 January 2018

1 reference

Selected Replicon Variants with Low-Level In Vitro Resistance to the Hepatitis C Virus NS5B Polymerase Inhibitor PSI-6130 Lack Cross-Resistance with R1479

21 January 2018

1 reference

Differential efficacy of protease inhibitors against HCV genotypes 2a, 3a, 5a, and 6a NS3/4A protease recombinant viruses.

21 January 2018

1 reference

Genotype differences in susceptibility and resistance development of hepatitis C virus to protease inhibitors telaprevir (VX-950) and danoprevir (ITMN-191).

21 January 2018

1 reference

Antiviral activity, safety, and pharmacokinetics of danoprevir/ritonavir plus PEG-IFN α-2a/RBV in hepatitis C patients

21 January 2018

1 reference

Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial

21 January 2018

1 reference

Faldaprevir (BI 201335), deleobuvir (BI 207127) and ribavirin oral therapy for treatment-naive HCV genotype 1: SOUND-C1 final results

21 January 2018

1 reference

Viral Determinants of Resistance to Treatment in Patients with Hepatitis C

21 January 2018

1 reference

Preliminary study of two antiviral agents for hepatitis C genotype 1.

21 January 2018

1 reference

Faldaprevir and deleobuvir for HCV genotype 1 infection.

21 January 2018

1 reference

JUMP-C: a randomized trial of mericitabine plus pegylated interferon alpha-2a/ribavirin for 24 weeks in treatment-naïve HCV genotype 1/4 patients

21 January 2018

1 reference

PROPEL: a randomized trial of mericitabine plus peginterferon alpha-2a/ribavirin therapy in treatment-naïve HCV genotype 1/4 patients

21 January 2018

1 reference

RG7128 alone or in combination with pegylated interferon-α2a and ribavirin prevents hepatitis C virus (HCV) Replication and selection of resistant variants in HCV-infected patients

21 January 2018

1 reference

In vivo emergence of a novel mutant L159F/L320F in the NS5B polymerase confers low-level resistance to the HCV polymerase inhibitors mericitabine and sofosbuvir

21 January 2018

1 reference

Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C.

21 January 2018

1 reference

Exploratory study of oral combination antiviral therapy for hepatitis C.

21 January 2018

1 reference

ABT-450 combined with ritonavir, in addition to ABT-333 and ribavirin: a race for an interferon-free regimen to cure HCV infection.

21 January 2018

1 reference

Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection

21 January 2018

1 reference

Hepatitis C viral kinetics with the nucleoside polymerase inhibitor mericitabine (RG7128)

21 January 2018

1 reference

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

21 January 2018

1 reference

Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus

21 January 2018

1 reference

Effect of IL28B genotype on early viral kinetics during interferon-free treatment of patients with chronic hepatitis C.

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/LIV.12588

1 reference

30 July 2017

1 reference